Prospective Study
Copyright ©The Author(s) 2022.
World J Clin Oncol. Jun 24, 2022; 13(6): 529-539
Published online Jun 24, 2022. doi: 10.5306/wjco.v13.i6.529
Table 3 Serum carcinoembryonic antigen and response to treatment in responders and non-responders according to breast cancer type
ClassificationResponders
Non-responders
Median pre-CEA
Median post-CEA
P value
Median pre-CEA
Median post-CEA
P value
Hormonal classificationLuminal14.7 (5.4-50.6)3 (1-10)0.00122.39 (3.9-84.4)21.00 (10.6-164.15)0.26
Non-luminal1.85 (1-3.65)1.25 (0.5-3)0.0464.15 (0.85-10.17)5.65 (2.65-12.05)0.161
Genomic classificationLuminal14.7 (5.4-50.6)3 (1-10) 0.001 22.39 (3.9-84.47) 20.67 (10.6-164.17) 0.260
HER24 (1.2-4)3.25 (0.5-3.25)0.18 11.713_
TNBC1.85 (0.74-2.4)1.25 (0.67-1.88)0.1444 (0.5-5.6) 5.3 (2.2-9.2) 0.237